---
title: "Kesimpta (ofatumumab) in relapsing multiple sclerosis: Safety questions"
description: "Safety questions on Kesimpta (ofatumumab) in relapsing multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings, Side effects, Monitoring, Administration reactions, Safety evidence, and Vaccines. Questions: What are the contraindications for Kesimpta? What are the most common side effects of Kesimpta? Does Kesimpta increase the risk of infections? Can Kesimpta cause hepatitis B reactivation? 14 further questions follow. 18 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kesimpta (ofatumumab) in relapsing multiple sclerosis: Safety questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kesimpta](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf)

## Warnings

<a id="kesimpta-contraindications"></a>

### What are the contraindications for Kesimpta?

> “KESIMPTA is contraindicated in patients with: 
> • 
> Active HBV infection [see Warnings and Precautions (5.1)]. 
> • 
> History of hypersensitivity to ofatumumab or life-threatening injection-related reaction to KESIMPTA. 
> Hypersensitivity reactions have included anaphylaxis and angioedema [see Warnings and Precautions (5.2)].”

Source: [KESIMPTA: Prescribing information, page 3, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=3)

<a id="kesimpta-infections"></a>

### Does Kesimpta increase the risk of infections?

> “Serious, including life-threatening or fatal, bacterial, fungal, and new or reactivated viral infections have been observed 
> during and following completion of treatment with anti-CD20 B-cell depleting therapies. 
> In KESIMPTA Study 1 and Study 2 [see Clinical Studies (14)], the overall rate of infections and serious infections in 
> patients treated with KESIMPTA was similar to patients who were treated with teriflunomide (51.6% vs 52.7%, and 2.5% 
> vs 1.8%, respectively). The most common infections reported by KESIMPTA-treated patients in the randomized clinical 
> relapsing MS (RMS) trials included upper respiratory tract infection (39%) and urinary tract infection (10%). Delay 
> KESIMPTA administration in patients with an active infection until the infection is resolved.”

Source: [KESIMPTA: Prescribing information, page 3, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=3)

<a id="kesimpta-hepatitis-b-reactivation"></a>

### Can Kesimpta cause hepatitis B reactivation?

> “There were no reports of HBV reactivation in patients with MS treated with KESIMPTA. However, HBV reactivation, in 
> some cases resulting in fulminant hepatitis, hepatic failure, and death, has occurred in patients being treated with 
> ofatumumab for chronic lymphocytic leukemia (CLL) (at higher intravenous doses than the recommended dose in MS but 
> for a shorter duration of treatment) and in patients treated with other anti-CD20 antibodies.”

Source: [KESIMPTA: Prescribing information, page 3, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=3)

> “KESIMPTA is contraindicated in patients with active hepatitis B disease.”

Source: [KESIMPTA: Prescribing information, page 3, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=3)

<a id="kesimpta-pml"></a>

### Can Kesimpta cause PML (progressive multifocal leukoencephalopathy)?

> “Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral infection of the brain caused by the JC virus 
> (JCV) that typically occurs in patients who are immunocompromised, and that usually leads to death or severe disability.  
> Although no cases of PML have been reported for KESIMPTA in the RMS clinical studies, PML resulting in death has 
> occurred in patients being treated with ofatumumab for CLL (at substantially higher intravenous doses than the 
> recommended dose in MS but for a shorter duration of treatment). In addition, JCV infection resulting in PML has also 
> been observed in patients treated with other anti-CD20 antibodies and other MS therapies. At the first sign or symptom 
> suggestive of PML, withhold KESIMPTA and perform an appropriate diagnostic evaluation. Magnetic resonance imaging 
> (MRI) findings may be apparent before clinical signs or symptoms. Typical symptoms associated with PML are diverse, 
> progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, 
> disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. 
> If PML is confirmed, treatment with KESIMPTA should be discontinued.”

Source: [KESIMPTA: Prescribing information, page 4, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=4)

<a id="kesimpta-liver-injury"></a>

### Can Kesimpta cause liver problems?

> “Clinically significant liver injury, without findings of viral hepatitis, has been reported in the postmarketing setting in 
> patients treated with anti-CD20 B-cell depleting therapies approved for the treatment of MS, including KESIMPTA. Signs 
> of liver injury, including markedly elevated serum hepatic enzymes with elevated total bilirubin, have occurred weeks to 
> months after administration.  
> Patients treated with KESIMPTA found to have an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 
> greater than 3x the upper limit of normal (ULN) with serum total bilirubin greater than 2x ULN, are potentially at risk for 
> severe drug-induced liver injury. 
> Obtain liver function tests prior to initiating treatment with KESIMPTA [see Dosage and Administration (2.1)], and 
> monitor for signs and symptoms of any hepatic injury during treatment. Measure serum aminotransferases, alkaline 
> phosphatase, and bilirubin levels promptly in patients who report symptoms that may indicate liver injury, including new 
> or worsening fatigue, anorexia, nausea, vomiting, right upper abdominal discomfort, dark urine, or jaundice. If liver injury 
> is present and an alternative etiology is not identified, discontinue KESIMPTA.”

Source: [KESIMPTA: Prescribing information, page 5, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=5)

## Side effects

<a id="kesimpta-side-effects"></a>

### What are the most common side effects of Kesimpta?

> “Most common adverse reactions (incidence greater than 10%) are upper 
> respiratory tract infection, headache, injection-related reactions, and local 
> injection site reactions. (6.1)”

Source: [KESIMPTA: Prescribing information, page 1, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=1)

> “Table 1: Adverse Reactions in Patients With RMS With an Incidence of at Least 5% With KESIMPTA and a 
> Greater Incidence Than Teriflunomide (Pooled Study 1 and Study 2) 
> Adverse reactions 
> KESIMPTA 20 mg 
> N = 946 
> % 
> Teriflunomide 14 mg 
> N = 936 
> % 
> Upper respiratory tract infections<sup>a</sup> 
> 39 
> 38 
> Injection-related reactions 
> (systemic) 
> 21 
> 15 
> Headache 
> 13 
> 12 
> Injection-site reactions (local) 
> 11 
> 6 
> Urinary tract infection 
> 10 
> 8 
> Back pain 
> 8 
> 6 
> Blood immunoglobulin M 
> decreased 
> 6 
> 2”

Source: [KESIMPTA: Prescribing information, page 6, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=6)

> “<sup>a</sup>Includes the following: nasopharyngitis, upper respiratory tract infection, influenza, sinusitis, pharyngitis, rhinitis, viral upper 
> respiratory infection, tonsillitis, acute sinusitis, pharyngotonsillitis, laryngitis, pharyngitis streptococcal, viral rhinitis, sinusitis 
> bacterial, tonsillitis bacterial, viral pharyngitis, viral tonsillitis, chronic sinusitis, nasal herpes, tracheitis.”

Source: [KESIMPTA: Prescribing information, page 6, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=6)

<a id="kesimpta-discontinuation-rates"></a>

### How often did patients stop Kesimpta because of side effects (ASCLEPIOS)?

> “Pooled data from both clinical trials show that treatment discontinuation rates due to adverse events were similar between KESIMPTA (5.7%) and Aubagio (5.2%)<sup>2</sup>”

Source: [KESIMPTA: Safety Profile, captured 2026-11-13](https://www.kesimptahcp.com/safety/safety-profile#:~:text=Pooled%20data%20from%20both%20clinical,between%20KESIMPTA%20%285.7%25%29%20and%20Aubagio)

> “The most common cause of discontinuation in patients treated with KESIMPTA was low IgM (3.3%), defined in trial protocols as IgM at 10% below the LLN<sup>1</sup>”

Source: [KESIMPTA: Safety Profile, captured 2026-11-13](https://www.kesimptahcp.com/safety/safety-profile#:~:text=The%20most%20common%20cause%20of,IgM%20at%2010%25%20below%20the)

## Monitoring

<a id="kesimpta-immunoglobulins"></a>

### Does Kesimpta lower immunoglobulin (IgG and IgM) levels?

> “As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in 
> immunoglobulin M (IgM) was reported in 7.7% of patients treated with KESIMPTA compared to 3.1% of patients treated 
> with teriflunomide in RMS clinical trials [see Adverse Reactions (6.1)]. Treatment was discontinued because of decreased 
> immunoglobulins in 3.4% of patients treated with KESIMPTA and in 0.8% of patients treated with teriflunomide. No 
> decline in immunoglobulin G (IgG) was observed at the end of the study. Monitor the levels of quantitative serum 
> immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after 
> discontinuation of therapy until B-cell repletion. Consider discontinuing KESIMPTA therapy if a patient with low 
> immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged 
> hypogammaglobulinemia requires treatment with intravenous immunoglobulins.”

Source: [KESIMPTA: Prescribing information, page 5, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=5)

> “In Study 1 and Study 2, a decrease in the mean level of IgM was observed in KESIMPTA-treated patients but was not 
> associated with an increased risk of infections [see Warnings and Precautions (5.3)]. In 14.3% of patients in Study 1 and 
> Study 2, treatment with KESIMPTA resulted in a decrease in a serum IgM that reached a value below 0.34 g/L. 
> KESIMPTA was associated with a decrease of 4.3% in mean IgG levels after 48 weeks of treatment and an increase of 
> 2.2% after 96 weeks.”

Source: [KESIMPTA: Prescribing information, page 6, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=6)

> “Monitor the level of immunoglobulins at the beginning, during, and after discontinuation of treatment with KESIMPTA until B-cell repletion”

Source: [KESIMPTA: Safety Profile, captured 2026-11-13](https://www.kesimptahcp.com/safety/safety-profile#:~:text=Monitor%20the%20level%20of%20immunoglobulins,with%20KESIMPTA%20until%20B%2Dcell%20repletion)

Note: The kesimptahcp.com safety page states that 14.3% of KESIMPTA-treated patients in the ASCLEPIOS trials experienced a decrease in IgM. In the Prescribing Information, 14.3% is the proportion whose serum IgM fell below 0.34 g/L, and 7.7% is the proportion with a reported decrease in IgM.

## Administration reactions

<a id="kesimpta-injection-reactions"></a>

### How common are Kesimpta injection reactions?

> “In Study 1 and Study 2, systemic and local injection reactions were reported in 21% and 11% of patients treated with 
> KESIMPTA, compared to 15% and 6% of patients treated with teriflunomide who received matching placebo injections, 
> respectively”

Source: [KESIMPTA: Prescribing information, page 4, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=4)

> “The incidence of injection-related reactions (systemic) was highest with the first injection (14.4%), decreasing with 
> subsequent injections (4.4% with second, less than 3% with third injection). Injection-related reactions were mostly 
> (99.8%) mild to moderate in severity. Two (0.2%) patients treated with KESIMPTA reported serious injection-related 
> reactions. There were no life-threatening injection-related reactions. Most frequently reported symptoms (2% or greater) 
> included fever, headache, myalgia, chills, and fatigue.”

Source: [KESIMPTA: Prescribing information, page 6, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=6)

> “In addition to systemic injection-related reactions, local reactions at the administration site were very common. Local 
> injection-site reactions were all mild to moderate in severity. The most frequently reported symptoms (2% or greater) 
> included erythema, pain, itching, and swelling”

Source: [KESIMPTA: Prescribing information, page 6, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=6)

<a id="kesimpta-injection-reaction-management"></a>

### How are Kesimpta injection-related and hypersensitivity reactions managed?

> “If systemic injection-related reactions occur, initiate appropriate therapy. Patients who experience 
> symptoms of systemic injection-related reactions or hypersensitivity reactions with KESIMPTA should be instructed to 
> seek immediate medical attention. 
> If a hypersensitivity reaction or life-threatening systemic injection-related reaction occurs, immediately and permanently 
> discontinue KESIMPTA [see Contraindications (4)]. If restarting KESIMPTA after a severe (but not life-threatening) 
> systemic injection-related reaction or other event after which rechallenge is considered appropriate, administer the next 
> KESIMPTA injection under clinical observation. If a mild to moderate injection-related reaction occurs, consider 
> rechallenge under clinical observation. 
> Local injection-site reaction symptoms observed in clinical studies included erythema, swelling, itching, and pain. If local 
> injection-related reactions occur, symptomatic treatment is recommended.”

Source: [KESIMPTA: Prescribing information, page 5, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=5)

## Safety

<a id="kesimpta-cancer-risk-studies"></a>

### Have nonclinical carcinogenicity or mutagenicity studies been done for Kesimpta?

> “No carcinogenicity studies have been conducted to assess the carcinogenic potential of ofatumumab.”

Source: [KESIMPTA: Prescribing information, page 10, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=10)

> “No studies have been conducted to assess the mutagenic potential of ofatumumab. As an antibody, ofatumumab is not 
> expected to interact directly with DNA.”

Source: [KESIMPTA: Prescribing information, page 10, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=10)

<a id="kesimpta-anti-drug-antibodies"></a>

### Does Kesimpta cause anti-drug antibodies (immunogenicity)?

> “Treatment-induced anti-drug antibodies (ADAs) were detected in 2 of 914 (0.2%) KESIMPTA-treated patients; no 
> patients with treatment-enhancing or neutralizing ADAs were identified. There was no impact of positive ADA titers on 
> pharmacokinetics, safety profile or B-cell kinetics in any patient; however, these data are not adequate to assess the 
> impact of ADAs on the safety and efficacy of KESIMPTA.”

Source: [KESIMPTA: Prescribing information, page 7, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=7)

## Safety evidence

<a id="kesimpta-long-term-side-effects"></a>

### What are the long-term infection and immunoglobulin effects of Kesimpta (ALITHIOS)?

> “Mean IgG levels remained >LLN (5.65 g/L) in 96.8% of participants at all assessments<sup>5</sup>”

Source: [KESIMPTA: Safety Profile, captured 2026-11-13](https://www.kesimptahcp.com/safety/safety-profile#:~:text=Mean%20IgG%20levels%20remained%20%3ELLN,96.8%25%20of%20participants%20at%20all)

> “Mean IgM levels decreased but remained >LLN (0.4 g/L) and were >LLN at all assessments in 64.5% of participants<sup>5</sup>”

Source: [KESIMPTA: Safety Profile, captured 2026-11-13](https://www.kesimptahcp.com/safety/safety-profile#:~:text=Mean%20IgM%20levels%20decreased%20but,all%20assessments%20in%2064.5%25%20of)

> “The proportion of participants with Ig-related AEs leading to KESIMPTA interruption or discontinuation due to low IgG was 0.2%/0.2% and for low IgM was 10.4%/3.6%<sup>5</sup>”

Source: [KESIMPTA: Safety Profile, captured 2026-11-13](https://www.kesimptahcp.com/safety/safety-profile#:~:text=The%20proportion%20of%20participants%20with,and%20for%20low%20IgM%20was)

> “Incidence of serious infections was consistent with that in the Phase 3 ASCLEPIOS I and II trials and did not increase with treatment up to 7 years despite the COVID-19 pandemic<sup>5</sup>”

Source: [KESIMPTA: Safety Profile, captured 2026-11-13](https://www.kesimptahcp.com/safety/safety-profile#:~:text=Incidence%20of%20serious%20infections%20was%20consistent,7%20years%20despite%20the%20COVID%2D19)

> “The most frequently reported serious infections were COVID-19 (2.59%), urinary tract infection (1.01%), lower respiratory tract infection (excluding COVID-19; 0.96%) and appendicitis (0.76%)<sup>18</sup>”

Source: [KESIMPTA: Safety Profile, captured 2026-11-13](https://www.kesimptahcp.com/safety/safety-profile#:~:text=The%20most%20frequently%20reported%20serious,%28excluding%20COVID%2D19%3B%200.96%25%29%20and%20appendicitis)

> “ALITHIOS study design: ALITHIOS is an open-label, umbrella extension, Phase 3b, single-arm study evaluating long-term (up to 7 years) data. The primary objective was to assess safety and tolerability (N=1969) in patients with RMS who had at least 1 dose of KESIMPTA (20mg SC) (including drop outs) from the ASCLEPIOS I/II, APLIOS, and APOLITOS trials. APLIOS (N=284) was a phase 2,12-week, open-label, parallel-group study. APOLITOS (N=62) is a phase 2, 24-week, double blind, placebo-controlled, parallel-group core-part followed by an open-label extension-part for up to 48 weeks, study in Japan and Russia. The secondary objective was to assess efficacy (N=1367) in patients with RMS who had at least 1 dose of KESIMPTA (20mg SC) from the ASCLEPIOS I and II trials who continued or switched to KESIMPTA treatment. A long-term (up to 7 years) analysis (n=465) was conducted to evaluate efficacy in the recently diagnosed treatment-naïve subgroup treated with KESIMPTA.<sup>5-10</sup>”

Source: [KESIMPTA: Safety Profile, captured 2026-11-13](https://www.kesimptahcp.com/safety/safety-profile#:~:text=ALITHIOS%20study%20design%3A%20ALITHIOS%20is,diagnosed%20treatment%2Dna%C3%AFve%20subgroup%20treated%20with)

> “No conclusions of clinical outcomes can be drawn.”

Source: [KESIMPTA: Safety Profile, captured 2026-11-13](https://www.kesimptahcp.com/safety/safety-profile#:~:text=No%20conclusions%20of%20clinical%20outcomes%20can%20be%20drawn.)

<a id="kesimpta-covid-19-outcomes"></a>

### What happened to Kesimpta patients with COVID-19 in ALITHIOS (through September 2022)?

> “COVID-19 related data—Analysis of data from December 2019 to September 25, 2022”

Source: [KESIMPTA: Safety Profile, captured 2026-11-13](https://www.kesimptahcp.com/safety/safety-profile#:~:text=COVID%2D19%20related%20data%E2%80%94Analysis%20of%20data%20from%20December%202019%20to%20September%2025%2C%202022)

> “648 (38%) of the 1703 patients (as of September 25, 2022) enrolled in ALITHIOS who received KESIMPTA reported that they had contracted COVID-19”

Source: [KESIMPTA: Safety Profile, captured 2026-11-13](https://www.kesimptahcp.com/safety/safety-profile#:~:text=648%20%2838%25%29%20of%20the%201703,that%20they%20had%20contracted%20COVID%2D19)

> “The open-label extension study is not blinded and not controlled”

Source: [KESIMPTA: Safety Profile, captured 2026-11-13](https://www.kesimptahcp.com/safety/safety-profile#:~:text=The%20open%2Dlabel%20extension%20study%20is%20not%20blinded%20and%20not%20controlled)

> “50 cases were considered serious with 82% recovery rate at the cutoff; there were 5 fatal outcomes”

Source: [KESIMPTA: Safety Profile, captured 2026-11-13](https://www.kesimptahcp.com/safety/safety-profile#:~:text=50%20cases%20were%20considered%20serious,there%20were%205%20fatal%20outcomes)

> “No statistical or clinical conclusion can be made.”

Source: [KESIMPTA: Safety Profile, captured 2026-11-13](https://www.kesimptahcp.com/safety/safety-profile#:~:text=No%20statistical%20or%20clinical%20conclusion%20can%20be%20made.)

## Vaccines

<a id="kesimpta-vaccines-before-starting"></a>

### When should vaccines be given before starting Kesimpta?

> “Because vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation 
> until B-cell repletion, administer all immunizations according to immunization guidelines at least 4 weeks prior to 
> initiation of KESIMPTA for live or live-attenuated vaccines, and whenever possible, at least 2 weeks prior to initiation of 
> KESIMPTA for inactivated vaccines [see Warnings and Precautions (5.1)].”

Source: [KESIMPTA: Prescribing information, page 2, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=2)

<a id="kesimpta-live-vaccines"></a>

### Can patients get live vaccines while taking Kesimpta?

> “KESIMPTA may interfere with the effectiveness of inactivated vaccines. 
> The safety of immunization with live or live-attenuated vaccines following KESIMPTA therapy has not been studied. 
> Vaccination with live or live-attenuated vaccines is not recommended during treatment and after discontinuation until B-
> cell repletion [see Clinical Pharmacology (12.2)].”

Source: [KESIMPTA: Prescribing information, page 4, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=4)

<a id="kesimpta-covid-19-vaccine-response"></a>

### What COVID-19 mRNA vaccine antibody response was seen with Kesimpta (Phase 4 study)?

> “Humoral responses to COVID-19 vaccines
> were seen in 56% (14/25) of patients
> taking KESIMPTA at first post-vaccination
> serologic assessment ≥14 days after they
> received their second or third vaccine dose
> • Humoral immune response appears to be
> increased in patients who received 3 doses
> compared with those who received 2 doses
> - Overall humoral responses were seen in
> 78% (7/9) of patients receiving 3 doses vs
> 44% (7/16) of those receiving 2 doses”

Source: [KESIMPTA: FA-11487114.PDF, page 2, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11487114-kesimpta-vaccine-brochure_0/FA-11487114.PDF#page=2)

> “Interim results of a Phase 4, open-label study assessing the effects of KESIMPTA 
> on humoral immune response to COVID-19 vaccinations in patients with RMS<sup>8</sup>”

Source: [KESIMPTA: FA-11487114.PDF, page 2, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11487114-kesimpta-vaccine-brochure_0/FA-11487114.PDF#page=2)

> “Study design: Ongoing open-label, multicenter, single-cohort, prospective study that enrolled RMS patients (aged 18-55) who are currently receiving KESIMPTA for ≥1 month. First 		
> post-vaccination serologic assessment occurred ≥14 days after second or third dose followed by a second assessment 90 days thereafter. Patients with prior COVID-19 diagnosis, contraindication 
> to receiving a COVID-19 mRNA vaccine, recent major infections, and prior treatment with S1P receptor modulators or natalizumab <2 months prior to enrollment were excluded. Primary end point: 
> Achieving immune response to non-live COVID-19 mRNA vaccine as defined by a positive SARS-CoV-2 qualitative IgG Ab assay.<sup>8</sup>”

Source: [KESIMPTA: FA-11487114.PDF, page 2, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11487114-kesimpta-vaccine-brochure_0/FA-11487114.PDF#page=2)

> “Limitations: The population studied was heterogenous and sample size was limited. No conclusions of clinical outcomes can be drawn.”

Source: [KESIMPTA: FA-11487114.PDF, page 2, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11487114-kesimpta-vaccine-brochure_0/FA-11487114.PDF#page=2)

Note: The brochure cites these interim results to a poster presented at the ACTRIMS Forum, February 24-26, 2022.

<a id="kesimpta-infant-vaccination"></a>

### Can infants exposed to Kesimpta during pregnancy get live vaccines?

> “In infants of mothers treated with KESIMPTA during pregnancy, do not administer live or live-attenuated vaccines before 
> confirming the B-cell count is within normal range. Depletion of B-cells in these infants may increase the risks from live 
> or live-attenuated vaccines.  
> Inactivated vaccines may be administered, as indicated, prior to confirming the B-cell count is within normal range, but an 
> assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to 
> determine whether a protective immune response was mounted.”

Source: [KESIMPTA: Prescribing information, page 4, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=4)

## Related pages
- [Medical information: Kesimpta (ofatumumab): Relapsing multiple sclerosis](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis)
- [Indication](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/access-and-coverage)
